VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
USPH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
USPHU.S. Physical Therapy, Inc.
$83.17$1.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksUSPHFinancials

U.S. Physical Therapy, Inc. (USPH) Income Statement

30Y historyFree accessUpdated daily

Revenue growth is volatile, swinging from 30.0% in Q1 2026 to a -15.2% decline in Q2 2026, while gross margins have shown extreme instability, collapsing to 14.5% in Q1 2026 before partially recovering to 33.0% in Q2 2026, indicating significant cost structure challenges.

Income StatementBalance SheetCash FlowRatios

USPH Income Statement

Annual statement

USPH Income Statement

U.S. Physical Therapy, Inc. (USPH) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue704.3M780.99M671.35M604.8M553.14M495.02M422.97M481.97M453.91M414.05M356.55M331.3M305.07M264.06M252.09M237.01M211.23M201.41M187.69M151.69M135.19M132.12M118.31M105.57M94.74M80.95M63.22M49.94M44M38.8M32.2M
Revenue Growth %5.88%16.33%11%9.34%11.74%17.04%-12.24%6.18%9.63%16.13%7.62%8.6%15.53%4.75%6.36%12.2%4.88%7.31%23.73%12.2%2.33%11.68%12.07%11.43%17.04%28.04%26.61%13.49%13.4%20.5%29.32%
Cost of Goods Sold550.87M623.65M547.42M483.29M441.12M377.84M328.52M369.5M352.25M323.43M274.53M252.94M228.91M199.36M189.5M172.51M151.82M146.24M140.08M114.33M99.35M96.21M85.28M74.6M64.53M54.88M42.9M34.09M30.8M27.3M22.1M
COGS % of Revenue-79.85%81.54%79.91%79.75%76.33%77.67%76.66%77.6%78.11%77%76.35%75.03%75.5%75.17%72.79%71.87%72.61%74.64%75.37%73.49%72.82%72.08%70.67%68.11%67.8%67.86%68.27%70%70.36%68.63%
Gross Profit153.43M157.34M123.92M121.51M112.02M117.18M94.45M112.47M101.66M90.62M82.01M78.36M76.17M64.7M62.59M64.49M59.42M55.17M47.6M37.36M35.84M35.91M33.03M30.96M30.21M26.07M20.32M15.84M13.2M11.5M10.1M
Gross Margin %21.78%20.15%18.46%20.09%20.25%23.67%22.33%23.34%22.4%21.89%23%23.65%24.97%24.5%24.83%27.21%28.13%27.39%25.36%24.63%26.51%27.18%27.92%29.33%31.89%32.2%32.14%31.73%30%29.64%31.37%
Gross Profit Growth %-26.97%1.98%8.47%-4.4%24.07%-16.02%10.63%12.19%10.49%4.66%2.88%17.72%3.38%-2.96%8.54%7.7%15.9%27.41%4.24%-0.19%8.72%6.68%2.5%15.88%28.27%28.27%20.02%14.78%13.86%34.67%
Operating Expenses71.67M76.91M60.71M69.45M55.22M46.53M42.04M45.05M41.35M35.89M32.48M31.07M30.4M25.93M24.78M28.56M26.23M26.74M23.73M17.33M17.25M17.03M17.04M13.97M11.33M9.12M9.94M8.58M7.7M6.7M6.5M
OpEx % of Revenue-9.85%9.04%11.48%9.98%9.4%9.94%9.35%9.11%8.67%9.11%9.38%9.96%9.82%9.83%12.05%12.42%13.28%12.64%11.42%12.76%12.89%14.4%13.23%11.96%11.27%15.72%17.18%17.5%17.27%20.19%
Selling, General & Admin27.48M058.29M046.11M46.53M42.04M45.05M41.35M35.89M32.48M31.07M30.4M25.93M24.78M24.78M22.99M23.39M23.73M17.33M17.25M16.43M16.8M13.97M11.33M9.12M7.61M6.49M5.6M4.8M4.8M
SG&A % of Revenue--8.68%-8.34%9.4%9.94%9.35%9.11%8.67%9.11%9.38%9.96%9.82%9.83%10.45%10.88%11.62%12.64%11.42%12.76%12.43%14.2%13.23%11.96%11.27%12.03%12.99%12.73%12.37%14.91%
Research & Development0000000000000000000000000000000
R&D % of Revenue-------------------------------
Other Operating Expenses3M76.91M2.42M69.45M9.11M00000000003.79M3.24M3.35M000604K238K0002.33M2.09M2.1M1.9M1.7M
Operating Income84.23M80.43M63.21M52.06M56.8M70.65M52.41M67.42M60.31M54.73M49.53M47.29M45.77M38.77M37.8M35.93M33.19M28.43M23.88M20.04M18.6M18.88M15.99M17M18.87M16.95M10.38M7.27M5.5M4.8M3.6M
Operating Margin %11.96%10.3%9.42%8.61%10.27%14.27%12.39%13.99%13.29%13.22%13.89%14.28%15%14.68%15%15.16%15.71%14.11%12.72%13.21%13.76%14.29%13.52%16.1%19.92%20.94%16.42%14.55%12.5%12.37%11.18%
Operating Income Growth %-27.24%21.42%-8.34%-19.6%34.79%-22.26%11.79%10.21%10.49%4.73%3.33%18.05%2.56%5.21%8.26%16.76%19.06%19.17%7.74%-1.52%18.07%-5.91%-9.94%11.36%63.21%42.91%32.11%14.58%33.33%125%
EBITDA106.32M102.82M81.89M67.76M71.54M82.24M62.95M77.52M70.07M64.44M58.31M55.25M52.51M44.33M43.09M41.38M38.86M34.32M29.84M25.02M23.09M23.19M20.32M20.59M21.83M19.51M12.71M9.36M7.6M6.7M5.3M
EBITDA Margin %15.1%13.17%12.2%11.2%12.93%16.61%14.88%16.08%15.44%15.56%16.35%16.68%17.21%16.79%17.09%17.46%18.4%17.04%15.9%16.5%17.08%17.55%17.17%19.5%23.04%24.11%20.11%18.74%17.27%17.27%16.46%
EBITDA Growth %10.91%25.56%20.87%-5.29%-13.01%30.65%-18.8%10.63%8.74%10.51%5.55%5.21%18.44%2.88%4.13%6.49%13.21%15.02%19.27%8.36%-0.44%14.16%-1.33%-5.69%11.86%53.47%35.9%23.11%13.43%26.42%60.61%
D&A (Non-Cash Add-back)22.09M22.39M18.68M15.7M14.74M11.59M10.53M10.1M9.76M9.71M8.78M7.95M6.74M5.56M5.29M5.45M5.67M5.9M5.97M4.99M4.49M4.31M4.32M3.59M2.96M2.57M2.33M2.09M2.1M1.9M1.7M
EBIT55.94M87.27M68.22M58.68M61.35M74.14M67.15M72.98M62.25M54.82M49.63M47.38M45.79M38.78M38.41M36.87M33.78M28.26M24.14M20.04M18.6M20.53M16.5M16.94M18.79M16.95M10.38M7.27M5.5M4.8M3.6M
Net Interest Income-7.48M-9.35M-4.07M-5.53M-5.78M-942K-1.49M-2.03M-1.95M-20.97M-11.38M-7.16M-7.44M-531K-551K4.95M350K-344K-282K-28K332K361K146K-189K-214K-266K-780K0-700K0-700K
Interest Income98K105K3.94M3.77M00142K46K93K88K93K81K18K7K6K5.45M586K8K260K273K332K361K146K00000000
Interest Expense-1.25M9.46M8.02M9.3M5.78M942K1.63M2.08M2.04M21.06M11.48M7.24M7.45M538K557K496K236K352K542K301K000189K214K266K780K727K700K0700K
Other Income/Expense-16.78M-2.62M-3M-2.69M-1.23M2.55M13.1M3.48M-103K-20.97M-11.38M-7.16M-1.07M-531K52K446K350K-344K-282K-5.75M-5.35M-5.61M-366K-5.16M-5.06M-5.45M-4.25M-3.3M-2.8M-2.3M-1.9M
Pretax Income67.45M77.81M60.21M49.38M55.57M73.2M65.51M70.91M60.21M33.76M38.15M46.34M44.7M38.24M37.25M40.88M33.54M28.08M16.51M14.28M13.25M14.3M10.78M11.78M13.72M11.5M6.14M3.96M2.7M2.5M1.7M
Pretax Margin %9.58%9.96%8.97%8.16%10.05%14.79%15.49%14.71%13.26%8.15%10.7%13.99%14.65%14.48%14.78%17.25%15.88%13.94%8.8%9.41%9.8%10.82%9.11%11.16%14.49%14.21%9.71%7.93%6.14%6.44%5.28%
Income Tax17.58M19.81M14.61M12.16M12.16M15.27M13.02M13.65M11.37M6.03M11.88M14.65M14.27M12.24M11.03M11.1M8.84M8.11M6.5M5.46M5.06M5.51M4.1M4.45M5.24M4.43M2.4M1.57M1.1M100K100K
Effective Tax Rate %26.06%25.46%24.26%24.62%21.89%20.86%19.88%19.25%18.88%17.87%31.14%31.62%31.93%32%29.62%27.15%26.36%28.88%39.4%38.27%38.17%38.53%38.03%37.78%38.15%38.53%39.15%39.58%40.74%4%5.88%
Net Income2.26M15.06M26.46M14.67M28.27M27.82M30.56M28.15M10.1M22.26M20.55M22.28M19.77M12.72M17.93M20.97M15.64M11.77M10M8.89M6.3M8.79M6.68M7.33M8.49M7.07M3.73M2.39M1.6M2.4M1.6M
Net Margin %0.32%1.93%3.94%2.43%5.11%5.62%7.23%5.84%2.23%5.38%5.76%6.72%6.48%4.82%7.11%8.85%7.41%5.84%5.33%5.86%4.66%6.65%5.64%6.94%8.96%8.74%5.91%4.79%3.64%6.19%4.97%
Net Income Growth %-92.86%-43.08%80.32%-48.09%1.61%-8.97%8.58%178.59%-54.61%8.3%-7.76%12.71%55.36%-29.05%-14.5%34.06%32.96%17.62%12.51%41.23%-28.38%31.64%-8.91%-13.63%20.04%89.32%56.02%49.63%-33.33%50%128.57%
Net Income (Continuing)34.97M58.01M45.6M37.22M43.41M57.92M52.49M57.26M48.84M27.72M26.27M26.49M30.42M26M26.64M29.78M24.7M19.97M17.09M8.81M8.19M9.18M12.04M7.33M8.49M7.07M3.73M2.39M1.6M2.4M1.6M
Discontinued Operations0000000000000-4.77M0000000-387K000000000
Minority Interest317.49M293.31M270.12M176.04M168.78M156.84M133.81M139.19M134.87M104.1M70.33M39.17M28.31M26.83M17.34M14.53M12.43M4.87M6.21M5.65M3.87M3.02M3.31M3.28M3.02M3.25M2.86M2.38M1.7M1.6M1M
EPS (Diluted)0.151.421.841.283.344.494.094.490.801.761.641.771.621.051.511.751.321.000.830.750.540.730.540.610.670.550.110.110.050.070.05
EPS Growth %-92.58%-22.83%43.75%-61.68%-25.61%9.78%-8.91%461.25%-54.55%7.32%-7.34%9.26%54.29%-30.46%-13.71%32.58%32%20.48%10.67%38.89%-26.03%35.19%-11.48%-8.96%21.82%400%0%135.55%-36.38%43.64%130.18%
EPS (Basic)-1.421.841.283.344.494.094.490.801.761.641.771.621.051.521.781.341.010.840.750.540.740.560.660.770.700.130.120.050.080.05
Diluted Shares Outstanding15.12M15.18M15.06M14.19M12.98M12.9M12.84M12.76M12.67M12.57M12.5M12.39M12.22M12.08M11.9M11.98M11.87M11.81M12.05M11.72M11.69M12.04M12.37M12.02M12.67M12.86M10.7M9.85M10.83M10.84M10.55M
Basic Shares Outstanding15.12M15.18M15.06M14.19M12.98M12.9M12.84M12.76M12.67M12.57M12.5M12.39M12.22M12.06M11.8M11.81M11.64M11.7M11.91M11.64M11.69M11.92M11.93M11.11M11.02M10.1M9.56M9.85M10.83M10.84M10.55M
Dividend Payout Ratio-181.66%100.3%164.43%75.42%67.45%13.45%51.71%115.45%45.23%41.41%33.44%29.71%38.03%50.28%18.07%-80.21%72.92%------------

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetAdequate
Cash FlowDeteriorating
Top Statement Risk

Gross margin volatility from cost structure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Erratic Revenue Trajectory Amid Cost Shifts

Revenue growth has been volatile, swinging from 30.0% in Q1 2026 to a sharp -15.2% decline in Q2 2026, suggesting underlying operational instability or significant cost reclassifications, as reported in recent financial statements.

The revenue pattern lacks durability, with a significant 30% surge in Q1 2026 immediately followed by a double-digit contraction. This extreme volatility indicates the growth may be driven by non-recurring events or accounting adjustments rather than consistent patient volume or pricing trends. Investors should monitor whether the Q2 2026 decline represents a normalization or the beginning of a more concerning trend.

Severe and Volatile Gross Margin Compression

Gross margins have shown extreme instability, collapsing to a concerning 14.5% in Q1 2026 from a historical range of roughly 17-25%, before partially recovering, which appears to signal significant cost structure vulnerability, based on USPH's reported quarterly data.

The gross margin profile is highly erratic, with the Q1 2026 low of 14.5% standing out as a potential red flag for operational control or reimbursement headwinds. This level is significantly below the peer NHC's 39.3% margin, suggesting USPH may lack the same pricing power or cost efficiencies. The subsequent rebound to 33% in Q2 2026 is positive but the inconsistency itself raises questions about the sustainability of the core business model's profitability.

SG&A Discipline Contrasts with COGS Volatility

SG&A expenses have been held relatively stable between $13.7M and $17.5M per quarter, demonstrating management's focus on overhead control, while COGS has swung wildly, driving the bulk of the income statement volatility, according to the company's quarterly filings.

The stability in SG&A, a fixed cost, indicates effective administrative expense management. However, the extreme variability in COGS, which fluctuated from $93.3M to $169.6M in just two quarters, suggests the primary risk to profitability lies in direct costs, possibly related to clinical labor, supplies, or reimbursement settlements. This cost profile means operational leverage is minimal, as gross profit is highly sensitive to factors outside management's apparent control.

Operating Income Stalled Despite Revenue Swings

Operating income has failed to scale meaningfully with revenue, hovering between roughly $15M and $25M, indicating weak operating leverage and that incremental revenue may be flowing to direct costs rather than the bottom line, as observed in USPH's financial results.

Despite a $45M sequential revenue increase from Q2 to Q1 2026, operating income only expanded by $7M, demonstrating that higher revenue is not translating proportionally to operating profit. This pattern implies that the business model struggles to achieve efficiency gains at scale, with incremental dollars largely absorbed by variable costs. The lack of operating leverage makes the company's profitability highly sensitive to revenue volume and mix.

Q1 2026 Marks a Profitability Deterioration Point

The first quarter of 2026 represents a clear negative inflection, marked by a collapse in gross margin to 14.5% and the first reported net loss in the dataset, signaling a potential structural shift in the company's cost or reimbursement environment.

This quarter broke from the historical pattern of positive, if modest, net income. The simultaneous occurrence of record revenue ($198.3M) with the lowest gross margin and a net loss suggests a severe operational or accounting event. The lasting impact is a higher baseline for SBC ($5.5M in Q2 vs. $0 in Q1) and a fundamentally altered profitability narrative that will require several strong quarters to repair.

Short-Seller Focus on Margin and Earnings Quality

A short thesis could center on the extreme volatility in gross margins and negative EPS in three of the last four quarters, questioning the sustainability of the business model and the quality of earnings, especially with SBC appearing irregularly.

The erratic gross margin, swinging from 14.5% to 33.0% in two quarters, could be framed as evidence of poor operational control or an unsustainable cost structure. Furthermore, the company has reported negative EPS in three of the most recent four quarters (Q1 2026, Q4 2025, and implied in others due to large swings), which undermines the investment case for a profitable services company. The irregular recognition of stock-based compensation ($5.5M in Q2 2026 after $0 in Q1) could also be highlighted as a potential earnings management tool.

USPH — Frequently Asked Questions

Quick answers to the most common questions about buying USPH stock.

What was U.S. Physical Therapy, Inc.'s (USPH) revenue in 2025?

For fiscal year 2025, U.S. Physical Therapy, Inc. (USPH) reported total revenue of $781.0M. This represents a 2325.4% increase compared to $32.2M in 1996.

Is U.S. Physical Therapy, Inc. (USPH) profitable?

U.S. Physical Therapy, Inc. (USPH) is profitable, generating $15.1M in net income for the fiscal year ending 2025 with a net profit margin of 1.9%.

What is U.S. Physical Therapy, Inc.'s operating profit margin?

U.S. Physical Therapy, Inc. (USPH) reported an operating income of $80.4M, resulting in an operating profit margin of 10.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is U.S. Physical Therapy, Inc.'s gross profit and gross margin?

U.S. Physical Therapy, Inc. (USPH) generated $157.3M in gross profit for the year, representing a gross profit margin of 20.1%. This demonstrates the company's core pricing power and production efficiency.